VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
AstraZeneca PLC vs Becton, Dickinson and Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisBecton, Dickinson and Company
BDX · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Becton, Dickinson and Company's moat claims, evidence, and risks.
View BDX analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 66 / 100 for Becton, Dickinson and Company).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Becton, Dickinson and Company has 5 segments (29.5% in Medical Essentials).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Strong vs Weak.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Becton, Dickinson and Company has 7 across 3.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Becton, Dickinson and Company
Medical Essentials
Single-use medical consumables and specimen collection systems
Global
Healthcare providers and clinical labs
Manufacturer
29.5%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
AstraZeneca PLC strengths
Becton, Dickinson and Company strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Becton, Dickinson and Company segments
Full profile >Medical Essentials
Competitive
Connected Care
Oligopoly
BioPharma Systems
Oligopoly
Interventional
Competitive
Life Sciences
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.